


Anti-parasitic drug prevents bacterial complications of scabies on mass scale

May 18 2022



The Northern Division of Fiji with scabies prevalence survey sites indicated (inset map shows location of Fiji and the Northern Division in the Pacific region). Credit: *The Lancet Regional Health - Western Pacific* (2022). DOI: 10.1016/j.lanwpc.2022.100433

An anti-parasitic drug, delivered on a mass scale, can prevent potentially dangerous bacterial complications of scabies in Fiji, according to a new study.

The research led by the Murdoch Children's Research Institute (MCRI), the Kirby Institute at UNSW Sydney and the Ministry of Health and Medical Services of Fiji, was the largest mass drug administration study for scabies in the region with the findings a big step forward in global scabies control.

Scabies is a contagious skin condition caused by a mite that burrows into the skin. The highly contagious disease causes itching, which can lead to complications such as severe skin infections and serious bacterial infections, bloodstream infections, kidney failure and heart disease.

Ivermectin has been used for decades in the treatment of parasitic infections. After the team of researchers proved ivermectin mass drug administration can be used to prevent the transmission of scabies, Murdoch Children's Dr. Li Jun Thean and her team, in collaboration with the Ministry of Health, administered the anti-parasitic drug to over 130,000 Fijians to help prevent bacterial complications.

For the study, ivermectin was administered to the whole population of the Northern Division of Fiji, which involved two doses of oral ivermectin or topical scabies cream, delivered alongside treatment for [lymphatic filariasis](#), another parasitic disease that Fiji has been working to eliminate through mass drug administration.

The findings, published in *The Lancet Regional Health—Western Pacific*, found that community-wide administration of ivermectin not only reduced the burden of scabies, by treating and preventing the disease, but also reduced hospitalizations and presentations to clinics for complications usually associated with the disease.

As the world's first study explicitly designed to investigate how ivermectin impacts on bacterial conditions associated with scabies, the findings provide key information to policymakers, including the World Health Organization who have identified scabies control with ivermectin as a high research priority.

The research team reported that, after the intervention, hospitalizations for skin and soft tissue infections due to scabies decreased by 17%, and primary healthcare presentations by 21%. Additionally, the number of people in the community with scabies and impetigo fell by about half.

Dr. Thean said this was the largest mass drug administration study for scabies in this region and the findings represented a big step forward in global scabies control.

Dr. Aalisha Sahukhan, Head of Health Protection at the Ministry of Health and Medical Services in Fiji, said scabies was an important public health issue facing her country, with the bacterial complications of the condition known to especially affect the [health](#) and well-being of children.

Kirby Institute Professor John Kaldor said scabies causes debilitating itch and sleep deprivation with socio-economic consequences such as stigma, missed school and substantial need for healthcare.

"About 200 million people have scabies, predominantly in resource-poor settings which contributes to 0.21% of disability. We aim to better treat scabies with our intervention in this region and hopefully reduce the number of people with scabies worldwide," he said.

Murdoch Children's Professor Andrew Steer said despite the tiny mite currently affecting hundreds of millions of people, it was possible to have a massive impact by treating whole populations.

In 2015, research by the Murdoch Children's, the Kirby Institute and the Fiji Ministry of Health showed that community-wide [ivermectin](#) treatment was able to reduce scabies prevalence by 94%.

MCRI and its partners are also leading a global program aiming to equip low- and [middle-income countries](#) with the tools and the resources to detect, monitor and control scabies in affected communities.

More information: Li Jun Thean et al, Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018–2020, *The Lancet Regional Health—Western Pacific* (2022). [DOI: 10.1016/j.lanwpc.2022.100433](https://doi.org/10.1016/j.lanwpc.2022.100433)

Provided by Murdoch Children's Research Institute

Citation: Anti-parasitic drug prevents bacterial complications of scabies on mass scale (2022, May 18) retrieved 21 June 2024 from <https://medicalxpress.com/news/2022-05-anti-parasitic-drug-bacterial-complications-scabies.html>

| |
|--|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|--|